https://orcid.org/0000-0003-2877-5919
References
- Pathania YS, Bhardwaj A. Urticaria and COVID-19 infection: a critical appraisal. J Dermatol Treat. 2020:1–4.
- Shanshal M. Low-dose systemic steroids, an emerging therapeutic option for COVID-19 related urticaria. J Dermatol Treat. 2020:1–2.
- Fine LM, Bernstein JA. Urticaria guidelines: consensus and controversies in the European and American guidelines. Curr Allergy Asthma Rep. 2015;15(6):30.
- Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414.
- Godse K, Bagadia A, Patil S, et al. "Busting" urticaria with a "burst" of steroids. Indian J Dermatol. 2014;159(6):618–619.
- Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270–1277.
- Cure E, Kucuk A, Cure MC. Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19). Rheumatol Int. 2020;40(7):1177–1179.
- Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016;137(2):474–481.
- Damme C, Berlingin E, Saussez S, et al. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(7):e300–e301.
- Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol.2020. DOI:10.1016/j.jaad.2020.06.1016